APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
10/08/2026
Voltar para busca
Dado oficial do USPTO
JETEMA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
28
Atualização mais recente
10/08/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5
Data de depósito
03/05/2019
Data de registro
09/06/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
09/06/2020
Última transação
10/08/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
03
Localização do titular
Gangwon-do, KR
Examinador
EINSTEIN, MATTHEW T
Unidade examinadora
M60
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
JETEMA CO., LTD.
Representantes
Kisuk Lee Harness, Dickey & Pierce, PLC
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
pharmaceutical agents affecting sensory organs; pharmaceutical agents affecting metabolism; pharmaceutical agents affecting peripheral nervous system; pharmaceutical preparations for urogenital organs; anti-inflammatory and antipyretic preparations; pharmaceutical agents affecting digestive organs; cardiovascular pharmaceutical preparations; ophthalmic preparations; allergy medications; pharmaceutical agents for epidermis; pharmaceutical preparations acting on the central nervous system; analgesics; pharmaceutical preparations for respiratory organs; medicines for dental purposes; Pharmaceutical preparations used in connection with anti-agingfor use in the treatment of glabellar linesfacial wrinklesasymmetries and defects and conditions of the human skinfor facial aesthetic surgeryfacial aesthetic reconstructionbreast aesthetic treatment procedures; topical antibioticsanti-inflammatoryanti-infectiveanti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutionsartificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disordersmuscle dystoniassmooth muscle disordersautonomic nerve disordersheadacheshyperhydrosissports injuriescerebral palsyspasmstremors and pain; dermatological formulationsmedicated dry skin lotions and creamsacne medications and medicated skin lightener lotions and creams; Oraltransdermalinjectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tractgastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that supportencourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's diseasedementiaAIDS-related dementiaCNSneurological disordersneurodegenerative disordersdepression; neuroprotective agent; antidepressants; pharmaceuticalsantipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin caremedicated skin cleanserstonersmoisturizersrejuvenatorsrehydrating creamslotions for the face and body
Publicações
Histórico de despachos e eventos da marca no USPTO.
28 publicações encontradas
ES71
TEAS SECTION 71 RECEIVED
11/05/2026
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
09/06/2025
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
17/10/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
29/09/2020
FIMP
FINAL DISPOSITION PROCESSED
29/09/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
09/09/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
09/06/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
24/03/2020
PUBO
PUBLISHED FOR OPPOSITION
24/03/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/03/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
19/02/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
30/01/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
29/01/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
29/01/2020
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
29/01/2020
RFNT
REFUSAL PROCESSED BY IB
23/08/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/08/2019
RFRR
REFUSAL PROCESSED BY MPU
01/08/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
16/07/2019
CNRT
NON-FINAL ACTION WRITTEN
15/07/2019
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
15/07/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/07/2019
CNRT
NON-FINAL ACTION WRITTEN
11/07/2019
DOCK
ASSIGNED TO EXAMINER
11/07/2019
MAFR
APPLICATION FILING RECEIPT MAILED
25/06/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
20/06/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
13/06/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace JETEMA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.